Search - tctmd.com

Displaying 181 - 200 of 266

Sort: Relevancy | Date

Lp(a) Linked to Higher ASCVD Risks in Diverse Patient Groups

News Daily News

Lp(a) Linked to Higher ASCVD Risks in Diverse Patient Groups

Michael O'Riordan

April 17, 2024

Should Conduction-System Pacing Be Top Choice for CRT?

News Conference News EHRA 2024

Should Conduction-System Pacing Be Top Choice for CRT?

April 15, 2024

HUDDLE Up! High BP and Cardiac Changes Prevalent in Retired NFL Players

News Conference News ACC 2024

HUDDLE Up! High BP and Cardiac Changes Prevalent in Retired NFL Players

Michael O'Riordan

April 15, 2024

Triglyceride-Lowering Therapies Provide Favorable Outcomes in Early Testing

News Conference News ACC 2024

Triglyceride-Lowering Therapies Provide Favorable Outcomes in Early Testing

Michael O'Riordan

April 12, 2024

Need a Statin for Primary Prevention? There’s an App for That

News Conference News ACC 2024

Need a Statin for Primary Prevention? There’s an App for That

Michael O'Riordan

April 10, 2024

Compared With Usual Care, Incorporating Inclisiran Early Cuts LDL

News Conference News ACC 2024

Compared With Usual Care, Incorporating Inclisiran Early Cuts LDL

Yael L. Maxwell

April 09, 2024

$Coronary Sinus Reducer Eases Symptoms in Refractory Angina: ORBITA-COSMIC$

News Conference News ACC 2024

Coronary Sinus Reducer Eases Symptoms in Refractory Angina: ORBITA-COSMIC

Michael O'Riordan

April 08, 2024

Study Bolsters AF’s Link to Brain Infarcts, Cognitive Impairment

News Conference News EHRA 2024

Study Bolsters AF’s Link to Brain Infarcts, Cognitive Impairment

April 08, 2024

Another Beta-blocker Blow: REDUCE-AMI Confirms No Benefit After Acute MI

News Conference News ACC 2024

Another Beta-blocker Blow: REDUCE-AMI Confirms No Benefit After Acute MI

Michael O'Riordan

April 07, 2024

Full AEGIS-II Results: Raising HDL With Apo A-I No Help After Acute MI

News Conference News ACC 2024

Full AEGIS-II Results: Raising HDL With Apo A-I No Help After Acute MI

Yael L. Maxwell

April 06, 2024

Comparison of an “Inclisiran First” Strategy With Usual Care in Patients With Atherosclerotic Cardiovascular Disease: Results From the VICTORION-INITIATE Randomized Trial

Presentation ACC 2024

Comparison of an “Inclisiran First” Strategy With Usual Care in Patients With Atherosclerotic Cardiovascular Disease: Results From the VICTORION-INITIATE Randomized Trial

Presenter: Michael J. Koren

April 06, 2024

Interatrial Shunt Falls Short in Sham-Controlled RELIEVE-HF

News Conference News ACC 2024

Interatrial Shunt Falls Short in Sham-Controlled RELIEVE-HF

Michael O'Riordan

April 06, 2024

Climbing Everest? Cardiac Arrhythmias Join Other Fabled Risks

News Daily News

Climbing Everest? Cardiac Arrhythmias Join Other Fabled Risks

Michael O'Riordan

April 04, 2024

TCTMD’s Top 10 Most Popular Stories for March 2024

News Opinion Editor's Corner

TCTMD’s Top 10 Most Popular Stories for March 2024

April 03, 2024

The ORBITA-2 Trial

Podcast TCTMD Talking Points

The ORBITA-2 Trial

April 03, 2024

The Promise of Pulsed-Field Ablation: Cautious Optimism Amid Some Unknowns

News Features

The Promise of Pulsed-Field Ablation: Cautious Optimism Amid Some Unknowns

March 29, 2024

ACC Chest Pain Pathway Performs Well Overall, Less So for Those With CAD

News Daily News

ACC Chest Pain Pathway Performs Well Overall, Less So for Those With CAD

Yael L. Maxwell

March 28, 2024

Most HFrEF Patients Eligible for Quadruple Therapy, but Few Get It

News Conference News ACC 2024

Most HFrEF Patients Eligible for Quadruple Therapy, but Few Get It

Michael O'Riordan

March 27, 2024

Icosapent Ethyl Lowers CV Risk Across Lp(a) Range: REDUCE-IT

News Conference News ACC 2024

Icosapent Ethyl Lowers CV Risk Across Lp(a) Range: REDUCE-IT

March 27, 2024

Intravascular Imaging Lowers Risk of MACE at 1 Year in Left Main PCI

News Daily News

Intravascular Imaging Lowers Risk of MACE at 1 Year in Left Main PCI

Michael O'Riordan

March 26, 2024

Country

First Name

Last Name

Email

Profession

Organization

Country

CAPTCHA

This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.